Trial Profile
A Phase I, Randomized, Single-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2017
Price :
$35
*
At a glance
- Drugs Streptococcal B vaccine conjugate (Primary)
- Indications Streptococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis
- 02 Dec 2010 Status changed from recruiting to completed added as reported by ClinicalTrials.gov (NCT01052935).
- 02 Dec 2010 Status changed from recruiting to completed added as reported by ClinicalTrials.gov (NCT01052935).
- 02 Dec 2010 Actual end date changed from Mar 2009 to Oct 2010 added as reported by ClinicalTrials.gov (NCT01052935).